We are pleased to announce a new audio interview with Madi Madiyalakan, CEO at Quest PharmaTech Inc. Quest PharmaTech Inc. trades publicly on the TSX-V under the symbol: QPT and on the OTC under the symbol: QPTFF
About Quest PharmaTech, Inc.
Quest PharmaTech Inc. (Quest) is a publicly traded (TSX Venture), Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds, and monoclonal antibodies that target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining these antibodies with other cancer therapies such as chemotherapy or photodynamic therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone.
The Company’s lead product candidate, Oregovomab, an immunotherapeutic product for the treatment of ovarian cancer is currently undergoing a multi-center Phase IIb clinical trial in Italy. Enrollment in this clinical trial has been completed. This is the first of three carefully planned proof-of-concept clinical trials to establish the superiority of combinatorial immunotherapy either with front-line chemotherapy consisting of carboplatin/paclitaxel in ovarian cancer, gemcitabine in pancreatic cancer, or with the addition of an immunoadjuvant. The Company hopes that successful results from these studies will lead to the design of a definitive product registration study.
About Dr. Madi Madiyalakan
Dr. Madiyalakan is the CEO of Quest PharmaTech since August, 2006; and Director since July, 2004. He was one of the founders of SonoLight Pharmaceuticals Corp. (served as its CEO and Director), CanBiocin Inc. (served as President, CEO and Director) and AltaRex Corp. (served as Vice-President, Planning and Chief Scientific Officer). Between 1987 and 1995 Dr. Madiyalakan served in various senior positions at Biomira Inc. Dr. Madiyalakan holds a Masters (Chemistry) and Ph.D. (Biochemistry) and a Certificate in Management Development. In addition, he has over 25 years of academic and industrial research experience on an international basis. He has published extensively and been an inventor of a number of patents.